Ignite Creation Date:
2024-05-06 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 12:29 PM
Study NCT ID:
NCT03244371
Status:
UNKNOWN
Last Update Posted:
2017-08-09
First Post:
2017-08-07
Brief Title:
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents DAA on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents DAA on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
Status:
UNKNOWN
Status Verified Date:
2017-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HCURE
Brief Summary:
Spontaneous recovery of patients infected with HCV is related to the development of a cytotoxic immune response that is executed by specialized white blood cells the CD8 T cells which develop a virus-specific response In addition the natural killer NK cells provide a first-line innate cytotoxic response which is pivotal for the spontaneous clearing of HCV In patients where HCV infection settles chronically CD8 T lymphocytes and NK cells fall into a state of anergy induced by chronic viral challenge This anergic state is also found in the case of HIV infection and exacerbated by HIV-HCV coinfection The first therapeutic strategies against HCV were based on a treatment with interferon alpha which had an antiviral but also immunosuppressive effect In fact this therapeutic strategy was unable to help the recovery of the patients immune system that would be expected after HCV cure However interferon-free therapeutic strategies combining first generation direct antiviral agents DAA showed a positive effect on HCV antiviral immunity by enhancing the proliferative response of CD8 T cells and the cytotoxic and proinflammatory responses of NK cells in HCV monoinfected patients 4 5 Since HCV-targeted therapies based on combinations of the latest generation of DAA have nearly 100 cure rates and enable faster viral suppression over shorter treatment times a positive impact of these regimens on antiviral immunity is plausible This possibility would be particularly interesting in HIV-HCV co-infected patients where reactivation of the innate antiviral immunity may contribute to immune defenses against both viruses Moreover it has been previously reported a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1hepatitis C virus-coinfected patients receiving highly active antiretroviral therapy and treated with IFN alpharibavirin
To date the real impact on antiviral immunity of treatment as well as on HIV reservoir with the latest generation of DAA was not measured in HIV-HCV co-infected patients
The aim of this study is to analyze the impact of the cure of hepatitis C on the HIV DNA reservoir and antiviral function of CD8 and NK cells in a subgroup of patients receiving the latest generation DAAs for treatment of HCV infection as part of a program for a reduction of the prevalence of chronic hepatitis C patients co-infected HIV-HCV set up within the Immuno-Hematology Service of the Sainte Marguerite Hospital Research in routine care-Ethics committee Approval Sud- Méditerranée I ID RCB 2015-A01913-46 Principal Investigator Dr I Poizot-Martin
The analysis of HIV DNA NK and CD8 T lymphocyte antiviral immune response prior during and after anti-HCV treatment will need the collection of a biobank Indeed 25 mL peripheral blood will be collected at treatment initiation during an interim assessment at the end of treatment and six months post-treatment for a total of 100 ml of additional blood collection These analyzes will be performed by Dr C Tamalet for HIV DNA IHU-Méditerranée Infection and the team of Prof E Vivier DHU- Marseille Immunopole for NK and CD8 T lymphocyte antiviral immune response
To date the real impact on antiviral immunity of treatment as well as on HIV reservoir with the latest generation of DAA was not measured in HIV-HCV co-infected patients
The aim of this study is to analyze the impact of the cure of hepatitis C on the HIV DNA reservoir and antiviral function of CD8 and NK cells in a subgroup of patients receiving the latest generation DAAs for treatment of HCV infection as part of a program for a reduction of the prevalence of chronic hepatitis C patients co-infected HIV-HCV set up within the Immuno-Hematology Service of the Sainte Marguerite Hospital Research in routine care-Ethics committee Approval Sud- Méditerranée I ID RCB 2015-A01913-46 Principal Investigator Dr I Poizot-Martin
The analysis of HIV DNA NK and CD8 T lymphocyte antiviral immune response prior during and after anti-HCV treatment will need the collection of a biobank Indeed 25 mL peripheral blood will be collected at treatment initiation during an interim assessment at the end of treatment and six months post-treatment for a total of 100 ml of additional blood collection These analyzes will be performed by Dr C Tamalet for HIV DNA IHU-Méditerranée Infection and the team of Prof E Vivier DHU- Marseille Immunopole for NK and CD8 T lymphocyte antiviral immune response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-A01028-43 | OTHER | IDRCB | None |